TABLE 3.

Primary outcome measures

	Aspirin	No aspirin	Ticagrelor	No ticagrelor
ITT analysis set#	60	60	58	62
Baseline	1	6	4	1
	1.7 (0.2–11.3)	10 (4.5–20.8)	6.9 (2.6–17.3)	1.6 (0.2–10.9)
6 months	29	7	24	2
	48.3 (35.8–61)	11.7 (5.6–22.8)	41.4 (29.3–54.6)	3.2 (0.8–12.3)
PP analysis set¶	41	45	32	54
6 months	28	7	22	2
	68.3 (52.3–80.9)	15.6 (7.5–29.6)	68.8 (50.4–82.6)	3.7 (0.9–14.0)

Data are presented as n or % (95% CI). ITT: intention-to-treat; PP: per-protocol. ^#: descriptive statistics for the primary outcome of response for the comparative groups at baseline and 6 months for the ITT analysis set; ^¶: response is ASPI response in the aspirin and no-aspirin columns and adenosine diphosphate response in the ticagrelor and no-ticagrelor columns.